Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
342.5 GBX | -0.72% | -2.84% | -2.84% |
Mar. 13 | BTIG Adjusts Price Target on MaxCyte to $8 From $10, Maintains Buy Rating | MT |
Mar. 13 | MaxCyte loss widens in 2023 as core revenue declines 25% | AN |
- Stock
- Equities
- Stock MaxCyte, Inc. - London S.E.
- News MaxCyte, Inc.